Form 4: Arcutis EVP Sells Shares for Tax Obligations

Arcutis Biotherapeutics' Executive Vice President and Chief Medical Officer, Patrick Burnett, sold 2,622 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Summary

• Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc. (ARQT), sold 2,622 shares of common stock.
• The sale occurred on August 4, 2025, at a weighted average price of $14.3266 per share.
• Individual sale prices ranged from $13.965 to $14.675.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged sale.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
• Following the transaction, Patrick Burnett directly owns 112,846 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 6

Explanation: The sale is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is generally neutral to slightly positive as it indicates RSU vesting. However, it still represents a reduction in insider ownership, hence a slightly above neutral score.

Positives

• The sale was non-discretionary, specifically to cover tax withholding obligations from vested Restricted Stock Units, which is a common practice and not indicative of a lack of confidence in the company.
• The transaction was conducted under a Rule 10b5-1(c) plan, suggesting it was pre-scheduled and not based on new material non-public information.

Negatives

• A reduction in direct share ownership by a key executive, even if for tax purposes, slightly decreases their direct equity stake in the company.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Stakeholder Impact

• Shareholders: Minor dilution from the sale of shares, but the non-discretionary nature mitigates concerns about insider sentiment.

Key Dates

Recommendation

The sale of shares by Patrick Burnett is a standard transaction to cover tax obligations arising from the vesting of Restricted Stock Units and was executed under a pre-arranged 10b5-1 plan. This type of sale is not indicative of a change in management's outlook or confidence in the company's future prospects. Therefore, it does not provide new information that would alter a fundamental investment thesis, supporting a 'hold' recommendation.

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Withholding, Biotechnology, Pharmaceuticals